var title_f20_45_21200="Distal femoral Salter-Harris type IV fracture";
var content_f20_45_21200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal femoral Salter-Harris type IV fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comminuted Salter-Harris type IV fracture of the distal femur in a 14-year-old boy involved in a motor vehicle collision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Price CT, Herrera-Soto J. Extra-articular injuries of the knee. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21200=[""].join("\n");
var outline_f20_45_21200=null;
var title_f20_45_21201="Compound z-plasty";
var content_f20_45_21201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Compound Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple Z-plasties are used to manage large wounds or scars not amenable to a single Z-plasty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21201=[""].join("\n");
var outline_f20_45_21201=null;
var title_f20_45_21202="Examination of wrist extension";
var content_f20_45_21202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of wrist extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain with resisted wrist extension with the elbow in full extension is characteristic of lateral epicondylitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21202=[""].join("\n");
var outline_f20_45_21202=null;
var title_f20_45_21203="Renal actions prostaglandins";
var content_f20_45_21203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Renal actions of the prostaglandins and possible complications with nonsteroidal anti-inflammatory drugs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21203=[""].join("\n");
var outline_f20_45_21203=null;
var title_f20_45_21204="Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Drug information";
var content_f20_45_21204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17157?source=see_link\">",
"    see \"Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12872684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      norel&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12925543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12925582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cold, allergy, or sinus symptoms:",
"     </b>",
"     Oral: One tablet every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12925581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12925583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12925585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12925584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12926502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     norel&reg; SR: Acetaminophen 325 mg, chlorpheniramine maleate 8 mg, phenylephrine hydrochloride 40 mg, and phenyltoloxamine citrate 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12925586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be split; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12925545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of cold, allergy, or sinus symptoms caused from inhalation of airborne irritants",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12925560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Chest tightness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever, fatigue, psychotic episodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia, bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12925550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, chlorpheniramine, phenylephrine, phenyltoloxamine, or any component of the formulation; severe hypertension; narrow-angle glaucoma; acute asthma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12925551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or active liver disease, including viral hepatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric: Use with caution in patients with psychosis or other psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acetaminophen: Avoid or limit use of other acetaminophen-containing products; limit total acetaminophen dose to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Continued or worsening of symptoms could be a sign of a more serious medical problem and should be further evaluated by a healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13119619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12925564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12925546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12925547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12925548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, \"Potentiation of Oral Anticoagulant Therapy by Acetaminophen,\"",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, \"Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, \"Potentiation of Warfarin Anticoagulation by Acetaminophen,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, \"Interaction Between Paracetamol and Coumarin Anticoagulants,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, \"Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,\"",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, \"Warfarin and Acetaminophen Interaction,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, \"Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, \"The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21204/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16786 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21204=[""].join("\n");
var outline_f20_45_21204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12872684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925543\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925582\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925581\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925583\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925585\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925584\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926502\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925586\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925545\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925551\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298652\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13119619\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925564\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925546\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925547\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925548\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17157?source=related_link\">",
"      Acetaminophen, chlorpheniramine, phenylephrine, and phenyltoloxamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_45_21205="Butalbital, acetaminophen, caffeine, and codeine: Patient drug information";
var content_f20_45_21205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Butalbital, acetaminophen, caffeine, and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/30/3560?source=see_link\">",
"     see \"Butalbital, acetaminophen, caffeine, and codeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fioricet&reg; with Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3491790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may cause very bad liver problems. Your risk is higher if you take more than 4 grams of acetaminophen a day, drink beer, wine, or mixed drinks, or have liver disease. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat tension headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to butalbital, acetaminophen, caffeine, codeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more than 6 capsules per day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11590 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FDEBE4EB0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21205=[""].join("\n");
var outline_f20_45_21205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143585\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026775\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026777\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026776\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026781\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026782\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026784\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026779\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026780\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026785\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026786\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/30/3560?source=related_link\">",
"      Butalbital, acetaminophen, caffeine, and codeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_45_21206="Nelarabine: Drug information";
var content_f20_45_21206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nelarabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/12/12485?source=see_link\">",
"    see \"Nelarabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=see_link\">",
"    see \"Nelarabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arranon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atriance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1987965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1987995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      T-cell acute lymphoblastic leukemia (ALL), T-cell lymphoblastic lymphoma:",
"     </b>",
"     I.V.: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1, 3, and 5; repeat every 21 days until transplant, disease progression, or unacceptable toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1987994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=see_link\">",
"      see \"Nelarabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      T-cell acute lymphoblastic leukemia (ALL), T-cell lymphoblastic lymphoma:",
"     </b>",
"     I.V.: 650 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1 through 5; repeat every 21 days until transplant, disease progression, or unacceptable toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1987996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1987997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling, (although ARA-G clearance is decreased as renal function declines, data is insufficient for a dosing recommendation); monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1987998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); closely monitor with severe impairment (total bilirubin &gt;3 times ULN).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F1987999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neurologic toxicity  &ge;  grade 2: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic or other (non-neurologic) toxicity: Consider treatment delay.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1988006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arranon&reg;: 5 mg/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Atriance&trade;: 5 mg/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1987963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1988000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate I.V. hydration recommended to prevent tumor lysis syndrome; allopurinol may be used if hyperuricemia is anticipated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Infuse over 1 hour daily for 5 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Infuse over 2 hours on days 1, 3, and 5",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1987967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       Nelarabine may be confused with clofarabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1993681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric adverse reactions fell within a range similar to adults except where noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (15%), edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (50%), fever (23%), somnolence (7% to 23%; grades 2-4: 1% to 6%), dizziness (21%; grade 2: 8% adults), headache (15% to 17%; grades 2-4: 4% to 8%), hypoesthesia (6% to 17%; grades 2/3: children 5%, adults 12%), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Petechiae (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (41%), diarrhea (22%), vomiting (10% to 22%), constipation (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (95% to 99%; grade 4: 10% to 14%), neutropenia (81% to 94%; grade 4: children 62%, adults 49%), thrombocytopenia (86% to 88%; grade 4: 22% to 32%), leukopenia (38%; grade 4: 7%), neutropenic fever  (12%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (12%; grade 3: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (12% to 21%; grades 2/3: 11% to 14%), weakness (6% to 17%; grade 4: 1%), paresthesia (4% to 15%; grades 2/3: 3% to 4%), myalgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (25%), dyspnea (7% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (8%), sinus tachycardia (8%), chest pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Ataxia (2% to 9%; grades 2/3: children 1%, adults 8%), confusion (8%), insomnia (7%), depressed level of consciousness (6%; grades 2-4: 2%), depression (6%), seizure (grade 3: 1% adults; grade 4: 6% children), motor dysfunction (4%; grades 2/3: 2%), amnesia (3%; grade 2: 1%), balance disorder (2%; grade 2: 1%), sensory loss (1% to 2%), aphasia (grade 3: 1%), attention disturbance (1%), cerebral hemorrhage (grade 4: 1%), coma (grade 4: 1%), encephalopathy (grade 4: 1%), hemiparesis (grade 3: 1%), hydrocephalus (1%), intracranial hemorrhage (grade 4: 1%), lethargy (1%), leukoencephalopathy (grade 4: 1%), loss of consciousness (grade 3: 1%), mental impairment (1%), nerve paralysis (1%), neuropathic pain (1%), nerve palsy (1%), paralysis (1%), sciatica (1%), sensory disturbance (1%), speech disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; Metabolic: Hypocalcemia (8%), dehydration (7%), hyper-/hypoglycemia (6%), hypomagnesemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (9%), anorexia (9%), stomatitis (8%), abdominal distension (6%), taste perversion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Albumin decreased (10%), bilirubin increased (10%; grade 3: 7%, grade 4: 2%), AST increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (9%), back pain (8%), muscle weakness (8%), rigors (8%), limb pain (7%), abnormal gait (6%), noncardiac chest pain (5%), tremor (4% to 5%; grade 2: 2% to 3%), dysarthria (1%), hyporeflexia (1%), hypertonia (1%), incoordination (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (4%), nystagmus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pleural effusion (10%), epistaxis (8%), pneumonia (8%), sinusitis (7%), wheezing (5%), sinus headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (5% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Craniospinal demyelination, neuropathy (peripheral) (similar to Guillain-Barr&eacute; syndrome), opportunistic infection, pneumothorax, progressive multifocal leukoencephalopathy (PML), respiratory arrest, rhabdomyolysis, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1987972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1987973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Leukopenia, thrombocytopenia, anemia, and neutropenia (including neutropenic fever) are associated with treatment. Monitor blood counts regularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Severe neurotoxicity, including mental status changes, severe somnolence, seizure, and peripheral neuropathy (ranging from numbness to motor weakness or paralysis), has been reported. Observe closely for signs and symptoms of neurotoxicity; discontinue if &ge; grade 2. Adverse effects associated with demyelination or similar to Guillain-Barr&eacute; syndrome (ascending peripheral neuropathies) have also been reported. Neurologic toxicities may not fully return to baseline after treatment cessation.",
"     </b>",
"     Neurologic toxicity is dose-limiting. Risk of neurotoxicity may increase in patients with concurrent or previous intrathecal chemotherapy or history of craniospinal irradiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur as a consequence of leukemia treatment. May lead to life-threatening acute renal failure; adequate hydration and prophylactic allopurinol should be instituted prior to treatment to prevent hyperuricemia and TLS; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely. Risk of adverse reactions may be higher with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor closely. Ara-G clearance may be reduced with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Avoid administration of live vaccines.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1987980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: May diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1987969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1987970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1987971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9780665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant,  the decision to discontinue breast-feeding or discontinue nelarabine should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Arranon Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (50 mL): $739.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1988003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Closely monitor for neurologic toxicity (severe somnolence, seizure, peripheral neuropathy, confusion, ataxia, paresthesia, hypoesthesia, coma, or craniospinal demyelination); signs and symptoms of tumor lysis syndrome; hydration status; CBC with differential, liver and kidney function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atriance (AT, BE, CH, CZ, DE, DK, EE, FR, GB, GR, IE, IL, IT, NL, NO, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1987985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nelarabine, a prodrug of ara-G, is demethylated by adenosine deaminase to ara-G and then converted to ara-GTP. Ara-GTP is incorporated into the DNA of the leukemic blasts, leading to inhibition of DNA synthesis and inducing apoptosis. Ara-GTP appears to accumulate at higher levels in T-cells, which correlates to clinical response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1987987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nelarabine: Children: ~213 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Adults: ~197 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ara-G: Children: ~33 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Adults: ~50 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Nelarabine and ara-G: &lt;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; demethylated by adenosine deaminase to form ara-G (active); also hydrolyzed to form methylguanine. Both ara-G and methylguanine metabolized to guanine. Guanine is deaminated into xanthine, which is further oxidized to form uric acid, which is then oxidized to form allantoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Children: Nelarabine: 13 minutes, Ara-G: 2 hours; Adults: Nelarabine: 18 minutes, Ara-G: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Ara-G: Adults: 3-25 hours (of day 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (nelarabine 5% to 10%, ara-G 20% to 30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Blaney SM, Devidas M, et al, &ldquo;Phase II Study of Nelarabine (Compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report from the Children&rsquo;s Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3376-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/15908649/pubmed\" id=\"15908649\" target=\"_blank\">",
"        15908649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Commander LA, Seif AE, Insogna IG, et al, &ldquo;Salvage Therapy With Nelarabine, Etoposide, and Cyclophosphamide in Relapsed/Refractory Paediatric T-Cell Lymphoblastic Leukaemia and Lymphoma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2010, 150(3):345-51. PMID: 20528871",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/20528871/pubmed\" id=\"20528871\" target=\"_blank\">",
"        20528871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeAngelo DJ, Yu D, Johnson JL, et al, &ldquo;Nelarabine Induces Complete Remissions in Adults With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Cancer and Leukemia Group B Study 19801,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(12):5136-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/17344466/pubmed\" id=\"17344466\" target=\"_blank\">",
"        17344466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gandhi V, Plunkett W, Rodriguez CO Jr, et al, &ldquo;Compound GW506U78 in Refractory Hematologic Malignancies: Relationship Between Cellular Pharmacokinetics and Clinical Response,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(11):3607-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/9817282/pubmed\" id=\"9817282\" target=\"_blank\">",
"        9817282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gandhi V, Plunkett W, Weller S, et al, \"Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(8):2142-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/11304766/pubmed\" id=\"11304766\" target=\"_blank\">",
"        11304766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gandhi V, Tam C, O'Brien S, et al, &ldquo;Phase I Trial on Nelarabine in Indolent Leukemias,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(7):1098-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/18309944/pubmed\" id=\"18309944\" target=\"_blank\">",
"        18309944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      G&ouml;kbuget N, Basara N, Baurmann H, et al, &ldquo;High Single-Drug Activity of Nelarabine in Relapsed T-Lymphoblastic Leukemia/Lymphoma Offers Curative Option With Subsequent Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(13):3504-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/21715318/pubmed\" id=\"21715318\" target=\"_blank\">",
"        21715318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kisor DF, \"Nelarabine: A Nucleoside Analog With Efficacy in T-Cell and Other Leukemias,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(6):1056-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/15870141/pubmed\" id=\"15870141\" target=\"_blank\">",
"        15870141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kisor DF, Plunkett W, Kurtzberg J, et al, &ldquo;Pharmacokinetics of Nelarabine and 9-beta-D-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(5):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/10694549/pubmed\" id=\"10694549\" target=\"_blank\">",
"        10694549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurtzberg J, Ernst TJ, Keating MJ, et al, \"Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3396-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/45/21206/abstract-text/15908652/pubmed\" id=\"15908652\" target=\"_blank\">",
"        15908652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9466 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21206=[""].join("\n");
var outline_f20_45_21206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709168\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987961\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505580\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987965\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987995\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987994\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987996\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987997\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987998\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987999\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950132\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987963\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988000\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987967\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401809\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1993681\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987972\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987973\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299749\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987980\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987969\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987970\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987971\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9780665\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322890\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988003\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038862\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987985\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987987\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9466|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/12/12485?source=related_link\">",
"      Nelarabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=related_link\">",
"      Nelarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_45_21207="Chronic hepatitis C - low power Gomori trichrome";
var content_f20_45_21207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Chronic hepatitis C (low power, Gomori trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 21-year-old IV drug user was found to have persistently elevated ALT levels in the 50 to 100 U/L range (normal less than or equal to 30 U/L). A percutaneous liver biopsy showed enlargement of portal triads and minimal interface hepatitis (once termed \"piecemeal necrosis\") using the METAVIR scanning system in which fibrosis ranges from 0 to 4 and inflammation (activity) from 0 to 3. This patient had stage 2 fibrosis and grade 1 inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21207=[""].join("\n");
var outline_f20_45_21207=null;
var title_f20_45_21208="ECG Polymorphic VT tutorial";
var content_f20_45_21208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1043px;\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Single lead electrocardiogram (ECG) showing polymorphic ventricular tachycardia (VT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 150px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QRS complexes in polymorphic VT&nbsp;have markedly differing morphologies due to changes in the direction (vector) of myocardial activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21208=[""].join("\n");
var outline_f20_45_21208=null;
var title_f20_45_21209="Hereditary hypophosphatemic rickets and tumor-induced osteomalacia";
var content_f20_45_21209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Steven J Scheinman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21209/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/45/21209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term vitamin D-resistant rickets (VDRR) originally was used to describe a syndrome of hypophosphatemia and rickets",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    osteomalacia) that resembled vitamin D deficiency but did not respond to vitamin D replacement or pharmacologic doses of vitamin D. Most of these cases were caused by renal phosphate wasting, leading to the alternate name of \"phosphate diabetes.\" This disorder is now called hereditary hypophosphatemic rickets because the primary problem is phosphate wasting rather than true vitamin D resistance.",
"   </p>",
"   <p>",
"    By contrast, true vitamin D resistance is characterized by hypocalcemia as well as hypophosphatemia and results from an inherited defect in the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D or in the calcitriol receptor that limits the interaction with 1,25-dihydroxyvitamin D. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D dependent rickets type I'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Hereditary vitamin D resistant rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary forms of hypophosphatemic rickets include X-linked, autosomal dominant and autosomal recessive disease, as well as hypophosphatemic rickets with hypercalciuria. The X-linked form is most common; the other forms are rare, with fewer than 100 reported cases. An acquired disorder, tumor-induced (or oncogenic) osteomalacia, has similar clinical manifestations to the familial syndromes. In addition to hypophosphatemia, these disorders all have normal serum levels of calcium and parathyroid hormone. Most of these disorders also have high circulating levels of fibroblast growth factor 23 (FGF23), a circulating hormone that causes renal phosphate wasting and is a common final pathway (",
"    <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology and treatment of hereditary hypophosphatemic rickets and tumor-induced osteomalacia will be reviewed here. The clinical manifestations and evaluation of rickets and osteomalacia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     X-LINKED",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked hypophosphatemic rickets (XLH) is a dominant disorder with a prevalence of approximately one case per 20,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of X-linked hypophosphatemic rickets is not fully understood. A number of functional studies indicate that the renal tubular defect in patients with XLH and in the corresponding mouse model (Hyp mouse) is caused by one or more circulating factors rather than by a defect in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Because these circulating factors promote phosphate excretion and impair bone mineralization, they have been termed \"phosphatonins\" or \"minhibins\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene responsible for XLH was identified on chromosome Xp22.1 and named PHEX (",
"    <strong>",
"     Ph",
"    </strong>",
"    osphate regulating",
"    <strong>",
"     E",
"    </strong>",
"    ndopeptidase on the",
"    <strong>",
"     X",
"    </strong>",
"    chromosome) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/5\">",
"     5",
"    </a>",
"    ]. This gene codes for a cell surface-bound protein-cleaving enzyme. PHEX is expressed predominantly in bone and teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/6\">",
"     6",
"    </a>",
"    ], and the altered function of this bone-derived endopeptidase causes the abnormalities of XLH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/7\">",
"     7",
"    </a>",
"    ]. A large number of inactivating mutations in the PHEX gene can cause XLH and there is no obvious correlation between genotype and phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 118 families with at least one case of hypophosphatemic rickets, PHEX mutations were found in 87 percent of familial cases and in 72 percent of sporadic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principal phosphatonin involved in the pathogenesis of XLH is fibroblast growth factor 23 (FGF23). Mutations in PHEX (in bone tissue) indirectly alter the degradation and production of FGF23, causing increased circulating levels of the phosphatonin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/9\">",
"     9",
"    </a>",
"    ]. FGF23, in turn, acts as a counter-regulatory hormone to inhibit phosphate reabsorption by the",
"    <span class=\"nowrap\">",
"     sodium/phosphate",
"    </span>",
"    cotransporter in the kidney, acting through specific FGF receptors with the important co-factor klotho protein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/10\">",
"     10",
"    </a>",
"    ]. Elevated levels of FGF23 also appear an important common pathway for other forms of hereditary hypophosphatemic rickets, as well as tumor-induced osteomalacia, although the mechanisms for the increased FGF23 vary among these disorders (",
"    <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, FGF23 appears to mediate the renal phosphate-wasting of XLH, and the hypophosphatemia contributes to, but is not fully responsible for the bone demineralization and rickets. However, FGF23 may not mediate all of the clinical effects of XLH. Experimental evidence in transgenic animals suggests that the majority of the mineralization defect may involve mechanisms other than FGF23-mediated phosphate wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/11\">",
"     11",
"    </a>",
"    ]. Some of the other clinical manifestations of XLH (such as enthesiopathy and dental abnormalities) also may be mediated by mechanisms other than FGF23.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypophosphatemia, slow growth, and rickets or osteomalacia are the major clinical findings. Low serum phosphorus is often present soon after birth. However, it is only at the time of weight bearing that leg deformities (eg, bowing) and progressive departure from normal growth rate become sufficiently striking to attract medical attention. Most children have radiographic evidence of rickets, particularly at the growth plates around the knee, which can cause severe bone pain. The axial skeleton often has a dense appearance. Enthesopathy (calcification of tendons, ligaments, and joint capsules) is a common finding, particularly in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/12\">",
"     12",
"    </a>",
"    ]. Younger siblings of affected patients should be screened to diagnose the disorder before these complications develop. Screening can be accomplished by measuring fasting serum phosphorus, and if necessary, renal phosphorus excretion. &nbsp;",
"   </p>",
"   <p>",
"    Defects in dentin may cause dental abscesses and early tooth decay in young adults. Hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/13\">",
"     13",
"    </a>",
"    ], left ventricular hypertrophy, and craniosynostosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/14\">",
"     14",
"    </a>",
"    ] have been identified in many of these patients, although it is not clear if these abnormalities are due to the disease itself or to the treatment (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/15\">",
"     15",
"    </a>",
"    ]. In particular, there is an association between hypertension and hyperparathyroidism, which frequently develops as a consequence of treatment regimens that include oral phosphate supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/13\">",
"     13",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H30486909\">",
"     'Hyperparathyroidism'",
"    </a>",
"    below). Despite hypophosphatemia, muscle weakness is not a prominent feature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link&amp;anchor=H21#H21\">",
"     \"Developmental defects of the teeth\", section on 'Dentin defects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    XLH is completely penetrant, but the severity varies widely, even among members of the same family. Whether boys are more severely affected than girls is a matter of debate. However, in the largest reported series of XLH patients, no gender difference in disease severity was detected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to hypophosphatemia and a decreased tubular reabsorptive threshold for phosphorus, patients with XLH have normal serum levels of calcium, normal-to-high parathyroid hormone levels, increased (or normal) alkaline phosphatase activity, normal plasma calcidiol concentration, and normal or slightly reduced plasma calcitriol concentration. The last finding suggests that calcitriol synthesis is abnormal in XLH because calcitriol is expected to be elevated in the presence of hypophosphatemia. The defect appears to be at the level of translation of the 25(OH)D-1alpha-hydroxylase mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iliac bone biopsies (not necessary for diagnosis in uncomplicated cases) show osteomalacia and hypomineralized periosteocytic lesions that are typical for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of the PHEX mutation may be useful to confirm the diagnosis and mode of heritability. Early diagnosis in newborns may be facilitated by knowing which mutation runs in the family, but it is not clear whether this information improves clinical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy for XLH depend upon whether treatment is directed at children or adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current therapy for XLH has been used for more than 30 years and consists of the oral administration of phosphate and calcitriol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/19\">",
"     19",
"    </a>",
"    ]. The administration of phosphate increases the plasma phosphate concentration, which lowers the plasma ionized calcium concentration, and further reduces the plasma calcitriol concentration (by removing the hypophosphatemic stimulus to its synthesis). This causes secondary hyperparathyroidism because of both hypocalcemia and removal of the normal inhibitory effect of calcitriol on parathyroid hormone (PTH) synthesis. The elevated PTH levels can aggravate the bone disease and increase urinary phosphate excretion, thereby defeating the aim of oral therapy. The administration of calcitriol is necessary to increase the intestinal absorption of calcium, and to a lesser degree phosphate, in an effort to prevent secondary hyperparathyroidism. (See",
"    <a class=\"local\" href=\"#H30486909\">",
"     'Hyperparathyroidism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcitriol is administered in two doses per day (10 to 20",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per dose).",
"     </li>",
"     <li>",
"      Phosphorus is administered in four to five doses that are equally spaced throughout the 24-hour period; the starting dose is 40 mg of elemental",
"      <span class=\"nowrap\">",
"       phosphorus/kg",
"      </span>",
"      per day. In our experience, a nighttime dose is important to achieve satisfactory results. Some catch-up growth should be noticeable within the first year of therapy. If this does not occur despite good compliance, the daily phosphorus dose should be increased in steps of 250 mg to 500 mg up to a maximum of 3500",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A short-term study in eight children with XLH suggests that addition of a calcimimetic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    ) to the regimen may prevent secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/20\">",
"     20",
"    </a>",
"    ]. The rationale for this strategy is that reduction of PTH levels should limit the renal phosphate wasting caused by elevated FGF23, allow the use of lower doses of phosphate and calcitriol, and reduce the risk of nephrocalcinosis. Calcimimetics have been used effectively to reduce PTH in chronic kidney disease and in tumor-induced osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/21\">",
"     21",
"    </a>",
"    ]. However, long-term studies in children with XLH are necessary before calcimimetics can be generally recommended.",
"   </p>",
"   <p>",
"    Various forms of phosphate salts are available (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    ) with no obvious advantage of one preparation over another. Tablets usually contain 250 mg elemental phosphorus per pill. Children who cannot take pills can receive phosphorus supplementation in the form of Joulie's solution (155 g of dibasic anhydrous sodium phosphate and 64 g of phosphoric acid 85 percent per liter solution, corresponding to 50",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of elemental phosphorus).",
"   </p>",
"   <p>",
"    The amount of phosphorus supplementation is usually limited by the occurrence of diarrhea. If diarrhea is a problem, the dose of phosphorus should be decreased by 250 to 500 mg and then gradually re-increased in steps of 125 mg. The aim should be to administer the minimum amount of phosphorus that is sufficient for normal growth. Slow growth and persistently elevated alkaline phosphatase activity indicate inadequate dose of phosphorus or compliance with therapy.",
"   </p>",
"   <p>",
"    Children should be seen every three months to monitor height, serum concentrations of calcium, phosphate, alkaline phosphatase, creatinine, and urinary calcium excretion. Renal ultrasonography should be performed once per year to evaluate nephrocalcinosis (see below). A hand radiograph should be obtained once per year to exclude the reappearance of rickets and to determine bone age. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In the majority of prepubertal children who are treated with this regimen, radiological signs of rickets disappear, growth improves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and deformities of the lower limbs are prevented or corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/19\">",
"     19",
"    </a>",
"    ]. Other effects of therapy include elevation in the plasma phosphate concentration, increase in urinary calcium excretion, marked improvement in bone or joint pain, and a significant decrease in osteoid thickness and mean osteoid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/24\">",
"     24",
"    </a>",
"    ]. The characteristic hypomineralized periosteocytic lesions persist on biopsy even though the histologic appearance of osteomalacia improves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the aim of treatment is to achieve normal growth, therapy is maintained as long as the growth plates are open (usually up to the age of 15 to 17 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether adults should continue therapy on a routine basis. Histologic evidence of osteomalacia recurs after phosphorus and calcitriol are stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/18\">",
"     18",
"    </a>",
"    ]. However, most of these patients have few if any skeletal complaints. Such patients may not benefit from therapy, whereas they may experience complications. As a result, it may be preferable to restrict treatment to those patients who are symptomatic. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcitriol is administered in two doses per day (10 to 20",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per dose)",
"     </li>",
"     <li>",
"      Phosphate is administered in a dose of 1 to 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in three to four divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to children, once a patient reaches adult height and the epiphyses have fused, the goal of therapy is simply to manage generalized bone pain, if it occurs, and to cure any non-union fractures. The minimal dose to achieve this goal should be sought in each patient, and many patients will require no therapy at all. Adults should be monitored at least annually for serum phosphorus, calcium, creatinine, and PTH.",
"   </p>",
"   <p>",
"    It is less clear whether therapy should be resumed in affected women who become pregnant. However, because the plasma phosphate of the fetus is determined by diffusion across the placenta, it seems reasonable to maintain a higher level of phosphate than that in the untreated state during pregnancy. Studies are underway to determine if hypophosphatemia during pregnancy affects bone mineralization or development in the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two important complications of the treatment of XLH: nephrocalcinosis and hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30486902\">",
"    <span class=\"h4\">",
"     Nephrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis can be demonstrated on renal ultrasonography in up to 80 percent of patients with XLH and is associated with renal tubular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The renal calcifications are located primarily in the tubules and are composed exclusively of calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/26\">",
"     26",
"    </a>",
"    ]. The degree of calcium phosphate deposition correlates with the mean phosphate dose but not with the dose of calcitriol or the duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/24,26\">",
"     24,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most patients have a normal plasma creatinine concentration, the long-term effect of nephrocalcinosis on renal function is not known. Isolated cases of renal insufficiency have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of nephrocalcinosis is probably linked to intermittent episodes of hypercalcemia and hypercalciuria. These can result from an excessive calcitriol dose or from noncompliance with oral phosphate supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, careful monitoring and control of serum and urine calcium is necessary to minimize nephrocalcinosis. The dose of calcitriol should be reduced when hypercalcemia or hypercalciuria are present. The importance of strict adherence to the burdensome phosphorus supplementation schedule must be repeatedly emphasized to the patients and their caretakers.",
"   </p>",
"   <p>",
"    Studies in Hyp mice suggest that nonhypercalcemic analogues of calcitriol, such as 22-oxacalcitriol, may provide a similar increase in plasma phosphate without producing hypercalcemia or hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/4\">",
"     4",
"    </a>",
"    ]. These analogues have not been evaluated in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30486909\">",
"    <span class=\"h4\">",
"     Hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperparathyroidism has been reported in XLH. This usually occurs after years of treatment, but also may be present early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/28\">",
"     28",
"    </a>",
"    ]. It is thought that complexing of calcium with phosphate results in intermittent hypocalcemia and persistent stimulation of parathyroid hormone (PTH) release despite the administration of calcitriol. When this secondary hyperparathyroidism is not adequately controlled, autonomous (tertiary) hyperparathyroidism can occur, necessitating surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. There is preliminary evidence that addition of a calcimimetic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    ) to the regimen may prevent secondary hyperparathyroidism, as discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of adjuvant therapy have been tested to improve the efficacy or diminish side effects of the current therapy of XLH.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    can improve short-term growth in children with XLH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/31\">",
"     31",
"    </a>",
"    ]. This may translate into taller final height, as shown in a long-term study on six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/32\">",
"     32",
"    </a>",
"    ]. However, it is possible that treatment with growth hormone aggravates the preexistent disproportionate stature of such children (ie, increased ratio of trunk to leg length) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/33\">",
"     33",
"    </a>",
"    ]. Available data do not support the recommendation of growth hormone therapy outside of the study setting.",
"   </p>",
"   <p>",
"    Observational studies of children with XLH show that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , or hydrochlorothiazide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , decreases urinary calcium excretion and prevents progression of nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This approach may be useful in the management of hypophosphatemic rickets if the results are confirmed in other studies.",
"   </p>",
"   <p>",
"    A placebo-controlled trial on 15 patients with XLH tested the value of 24,25-dihydroxyvitamin D as a supplement to standard treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/36\">",
"     36",
"    </a>",
"    ]. The main effect was improved control of hyperparathyroidism. Unfortunately, 24,25 dihydroxyvitamin D is not available as a pharmaceutical agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     AUTOSOMAL DOMINANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few reports have described a renal phosphate-wasting syndrome with rickets or osteomalacia that is transmitted as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/37\">",
"     37",
"    </a>",
"    ]. This disorder is known as autosomal dominant hypophosphatemic rickets (ADHR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant hypophosphatemic rickets results from activating mutations in the fibroblast growth factor 23 (FGF23) gene on chromosome 12p13 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/38\">",
"     38",
"    </a>",
"    ]. The protein produced by the mutant FGF23 gene is resistant to protease cleavage, so circulating levels of FGF23 are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The elevated levels of FGF23 inhibit renal phosphate reabsorption; this is also an important mechanism in the pathogenesis of X-linked disease and tumor-induced osteomalacia (",
"    <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'X-linked'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Tumor-induced osteomalacia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course in autosomal dominant hypophosphatemic rickets is similar to that usually observed in X-linked disease. However, the age of onset varies and is related to the clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients with early-onset disease have phosphate wasting, rickets, and lower extremity deformities in childhood, but may lose the phosphate-wasting defect after puberty.",
"   </p>",
"   <p>",
"    Those who present after growth plate closure have bone pain, weakness, and fractures, but no lower extremity deformities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience is available in the treatment of autosomal dominant X-linked hypophosphatemic rickets. However, because the clinical, biochemical, and radiographic characteristics of autosomal dominant hypophosphatemic rickets are similar to those of X-linked disease, analogous treatment schedules are used. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'X-linked'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     AUTOSOMAL RECESSIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive hypophosphatemic rickets (ARHR), without hypercalcuria, has been described in a few kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/41\">",
"     41",
"    </a>",
"    ]. Affected individuals exhibit isolated renal phosphate wasting. The disorder is caused by inactivating mutations in the DMP1 gene, which encodes Dentin matrix protein 1 and results in increased FGF23 expression and defective osteocyte maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HYPOPHOSPHATEMIA WITH HYPERCALCIURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following three syndromes have a constellation of abnormalities that includes hypophosphatemia and hypercalciuria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)",
"     </li>",
"     <li>",
"      Dent's disease",
"     </li>",
"     <li>",
"      Idiopathic hypercalciuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypophosphatemic rickets with hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) has been described in a few kindreds and in several sporadic cases. The disorder is inherited in an autosomal recessive fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHRH appears to be caused by genetic mutations of the renal type 2 c sodium-phosphate cotransporter. In two reports on six affected kindreds with HHRH, the disease was mapped to chromosome 9q34, which contains the gene SLC34A3 that encodes the renal type 2 c sodium-phosphate co-transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Disease-related mutations in this cotransporter were detected in all examined families (",
"    <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomalacia is the presenting feature in most patients. However, milder forms may be underdiagnosed if the hypophosphatemia is mild; such patients present with hypercalciuria and nephrolithiasis but no signs of bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder differs from X-linked and autosomal dominant hypophosphatemic rickets in that the impairment is restricted to phosphate transport and plasma calcitriol concentrations are normal or appropriately elevated for the degree of hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/45\">",
"     45",
"    </a>",
"    ]. Hypercalciuria probably occurs because of high calcitriol levels and secondarily increased intestinal calcium absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the hypercalciuric form of hypophosphatemic rickets should be treated with phosphorus supplementation alone, using the same dosing schedule as described for XLH. Endogenous calcitriol levels are elevated and the addition of exogenous calcitriol may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, plasma calcitriol levels and urinary calcium excretion should be measured before initiating therapy. Phosphate replacement therapy appears to normalize the serum phosphate concentration within a few days and improves but does not cure the osteomalacia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'X-linked'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children should be seen every three months to monitor height; serum concentrations of calcium, phosphorus, alkaline phosphatase, and creatinine; and urinary calcium excretion. Renal ultrasound should be performed once per year to evaluate nephrocalcinosis. A hand radiograph should be obtained once per year to exclude the reappearance of rickets and to determine bone age. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dent's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dent's disease is an X-linked recessive syndrome in which a primary defect in the cells of the proximal renal tubule results in a phenotype of proximal tubular solute-wasting, hypercalciuria, nephrocalcinosis, kidney stones, renal failure, and in some cases rickets. The most consistent feature is low molecular weight (LMW) proteinuria; other evidence of proximal solute reabsorptive failure includes glycosuria, aminoaciduria, and phosphaturia, though not bicarbonaturia. When rickets occurs it is usually evident from early childhood, but it only occurs in about 25 percent of patients. In a hypophosphatemic child with rickets, if other features suggest Dent&rsquo;s disease, urinary LMW proteins (&beta;2 microglobulin, retinol-binding protein) should be measured. The disease results from mutations in the",
"    <em>",
"     CLCN5",
"    </em>",
"    gene encoding a voltage-gated chloride transporter in about 60 percent of patients, and with the",
"    <em>",
"     OCRL1",
"    </em>",
"    gene in another 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. The pathogenesis and clinical manifestations of this disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"     \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Idiopathic hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic hypercalciuria, which is a risk factor for kidney stone formation, often is associated with mild hypophosphatemia and elevated levels of calcitriol, and may represent a mild proximal tubular defect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TUMOR-INDUCED OSTEOMALACIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypophosphatemia with osteomalacia and, if growth plates are still open, rickets, can occur as an acquired disorder in association with a tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. The tumors, typically benign, often are small and of mesenchymal origin (eg, sclerosing type of hemangiopericytoma). Tumor-induced osteomalacia also is called oncogenic hypophosphatemic osteomalacia or simply oncogenic osteomalacia. Although primarily described in adults, tumor-induced osteomalacia can occur in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracts of the tumor inhibit phosphate transport in renal epithelial cells and produce both hypophosphatemia and reduced calcitriol production in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. The tumor extract affects only phosphate transport. In contrast to PTH, it has no effect on calcium metabolism, its action is not blocked by a PTH antagonist, and its effects do not appear to be mediated by cyclic AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phosphaturic hormone implicated in tumor-induced osteomalacia is FGF23 (",
"    <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"     figure 1",
"    </a>",
"    ). Increased FGF23 activity also occurs in patients with X-linked hypophosphatemia and autosomal dominant hypophosphatemic rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/18,60\">",
"     18,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A two-site enzyme-linked immunosorbent assay for human FGF-23 was used to measure human FGF23 in patients with oncogenic osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/60\">",
"     60",
"    </a>",
"    ]. Serum FGF23 was elevated in five of six patients with oncogenic osteomalacia before removal of the tumor and fell in all five patients in whom it was measured after surgery. In another 11 patients in whom oncogenic osteomalacia was suspected (but not confirmed by removal of the tumor), FGF23 levels were elevated in eight. These findings are consistent with a possible pathogenetic role for FGF23 in at least some patients with tumor-induced osteomalacia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D metabolism is abnormal in tumor-induced osteomalacia, as it is in X-linked and autosomal dominant hypophosphatemic rickets. Thus, plasma concentrations of calcitriol are reduced, even though elevated levels are to be expected in the presence of hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Thus, the underlying tubular defect that impairs phosphate reabsorption also appears to affect calcitriol synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tumor-induced osteomalacia should be suspected from the clinical constellation of acquired hypophosphatemia and osteomalacia or rickets in association with renal phosphate wasting (but no other proximal tubular defects) and an inappropriately low plasma calcitriol concentration. The phenotype is similar to X-linked and autosomal dominant hypophosphatemic rickets but the family history is negative and the disorder is acquired.",
"   </p>",
"   <p>",
"    Finding the tumors can be a major diagnostic challenge, and may involve total body magnetic resonance imaging (MRI) or scintigraphy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    labeled with indium-111 (as the tumors typically express somatostatin receptors) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. However, identification of the suspected tumor is often difficult because it is usually small and exists within bone. In a series of 10 patients with presumed tumor-induced osteomalacia, in whom identification of the culprit tumor was unsuccessful by traditional methods, systemic venous sampling for FGF23 levels identified the body region in which the putative tumor was located in eight patients. In each of these patients CT scan or MRI of the region identified the tumor, and surgical resection confirmed that this was the cause of the osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience is available in the treatment of oncogenic osteomalacia. However, because the clinical, biochemical, and radiological characteristics of tumor-induced osteomalacia are similar to those of X-linked disease, analogous treatment regimens are used. Therapy is continued until the causative tumor can be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/51\">",
"     51",
"    </a>",
"    ] or indefinitely if tumor removal is not tenable. Removal of the tumor leads to prompt reversal of the biochemical abnormalities and healing of the bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. The risk of nephrocalcinosis appears to be less than that in patients with XLH. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'X-linked'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is an alternative form of medical therapy that may be considered when the tumor cannot be found despite intensive search. In one case report, phosphate wasting and hypophosphatemia were corrected with octreotide therapy; this effect was presumably mediated by somatostatin receptor expression by the tumor, which was demonstrated by octreotide scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/62\">",
"     62",
"    </a>",
"    ]. However, not all such patients respond to octreotide [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21209/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31918878\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary hypophosphatemic rickets refers to several disorders in which the primary problem is renal phosphate wasting. These include X-linked, autosomal dominant and autosomal recessive disease, as well as hypophosphatemic rickets with hypercalciuria. The disorders are caused by mutations in one of the genes that control renal phosphate reabsorption (",
"      <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"       figure 1",
"      </a>",
"      ). The X-linked form is most common; the other forms are rare. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked hypophosphatemic rickets (XLH) is a dominant disorder caused by a variety of mutations in the PHEX (",
"      <strong>",
"       Ph",
"      </strong>",
"      osphate regulating",
"      <strong>",
"       E",
"      </strong>",
"      ndopeptidase on the",
"      <strong>",
"       X",
"      </strong>",
"      chromosome) gene. It is characterized by hypophosphatemia, slow growth, and rickets or osteomalacia; both boys and girls are affected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'X-linked'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Treatment for XLH consists of the oral administration of phosphate and calcitriol. The phosphate is given to replace renal losses, and calcitriol is necessary to increase the intestinal absorption of calcium, to prevent secondary hyperparathyroidism. This therapy is continued at least through adolescence; it is controversial whether adults should continue therapy on a routine basis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autosomal dominant hypophosphatemic rickets (ADHR) has been described in a few case reports. The clinical manifestations and treatment approaches are similar to those in X-linked disease, but vary with the age of onset. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Autosomal dominant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three syndromes have a constellation of abnormalities that includes hypophosphatemia and hypercalciuria: Hereditary hypophosphatemic rickets with hypercalciuria (HHRH), Dent's disease, and idiopathic hypercalciuria. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hypophosphatemia with hypercalciuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most patients with HHRH present with rickets",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      osteomalacia. However, milder forms may present with hypercalciuria and nephrolithiasis but no signs of bone disease. Unlike XLH, plasma calcitriol concentrations are normal or appropriately elevated for the degree of hypophosphatemia; treatment is with phosphorus supplementation alone. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hypophosphatemic rickets with hypercalciuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dent&rsquo;s disease is an inherited cause of nephrocalcinosis, with an X-linked recessive pattern of inheritance. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dent's disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor-induced osteomalacia is characterized by severe hypophosphatemia and osteomalacia, with renal phosphate wasting and an inappropriately low plasma calcitriol concentration, that occurs in association with a tumor. If growth plates are still open, rickets can occur. The tumors are typically benign, small and of mesenchymal origin. The pathways involved and clinical manifestations are similar to those of XLH (",
"      <a class=\"graphic graphic_figure graphicRef82448 \" href=\"UTD.htm?37/17/38174\">",
"       figure 1",
"      </a>",
"      ). Unlike XLH, the family history is negative and the disorder is acquired. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Tumor-induced osteomalacia'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25831617\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Frank Rauch and Dr. Zalman Agus, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/1\">",
"      Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010; 6:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/2\">",
"      Nesbitt T, Coffman TM, Griffiths R, Drezner MK. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 1992; 89:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/3\">",
"      Meyer RA Jr, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 1989; 4:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/4\">",
"      Xiao ZS, Crenshaw M, Guo R, et al. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol 1998; 275:E700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/5\">",
"      A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/6\">",
"      Liu S, Guo R, Quarles LD. Cloning and characterization of the proximal murine Phex promoter. Endocrinology 2001; 142:3987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/7\">",
"      Yuan B, Takaiwa M, Clemens TL, et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008; 118:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/8\">",
"      Gaucher C, Walrant-Debray O, Nguyen TM, et al. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet 2009; 125:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/9\">",
"      Benet-Pag&egrave;s A, Lorenz-Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/10\">",
"      Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/11\">",
"      Martin A, David V, Laurence JS, et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008; 149:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/12\">",
"      Polisson RP, Martinez S, Khoury M, et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 1985; 313:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/13\">",
"      Alon US, Monzavi R, Lilien M, et al. Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism. Pediatr Nephrol 2003; 18:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/14\">",
"      Murthy AS. X-linked hypophosphatemic rickets and craniosynostosis. J Craniofac Surg 2009; 20:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/15\">",
"      Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1997; 82:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/16\">",
"      Whyte MP, Schranck FW, Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 1996; 81:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/17\">",
"      Yuan B, Xing Y, Horst RL, Drezner MK. Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in the hyp-mouse. Endocrinology 2004; 145:3804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/18\">",
"      Marie PJ, Glorieux FH. Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int 1983; 35:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/19\">",
"      Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980; 303:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/20\">",
"      Alon US, Levy-Olomucki R, Moore WV, et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 2008; 3:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/21\">",
"      Geller JL, Khosravi A, Kelly MH, et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 2007; 22:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/22\">",
"      Sullivan W, Carpenter T, Glorieux F, et al. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1992; 75:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/23\">",
"      Verge CF, Cowell CT, Howard NJ, et al. Growth in children with X-linked hypophosphataemic rickets. Acta Paediatr Suppl 1993; 388:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/24\">",
"      Verge CF, Lam A, Simpson JM, et al. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991; 325:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/25\">",
"      Seikaly M, Browne R, Baum M. Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics 1996; 97:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/26\">",
"      Alon U, Donaldson DL, Hellerstein S, et al. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 1992; 120:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/27\">",
"      Tieder M, Blonder J, Strauss S, et al. Hyperoxaluria is not a cause of nephrocalcinosis in phosphate-treated patients with hereditary hypophosphatemic rickets. Nephron 1993; 64:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/28\">",
"      Carpenter TO, Mitnick MA, Ellison A, et al. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 1994; 78:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/29\">",
"      Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 1992; 75:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/30\">",
"      Knudtzon J, Halse J, Monn E, et al. Autonomous hyperparathyroidism in X-linked hypophosphataemia. Clin Endocrinol (Oxf) 1995; 42:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/31\">",
"      Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 1997; 100:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/32\">",
"      Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 2001; 138:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/33\">",
"      Haffner D, Nissel R, W&uuml;hl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 2004; 113:e593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/34\">",
"      Seikaly MG, Baum M. Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics 2001; 108:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/35\">",
"      Alon U, Chan JC. Effects of hydrochlorothiazide and amiloride in renal hypophosphatemic rickets. Pediatrics 1985; 75:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/36\">",
"      Carpenter TO, Keller M, Schwartz D, et al. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study. J Clin Endocrinol Metab 1996; 81:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/37\">",
"      Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/38\">",
"      ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/39\">",
"      White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/40\">",
"      Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/41\">",
"      Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/42\">",
"      Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/43\">",
"      Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/44\">",
"      Lorenz-Depiereux B, Benet-Pages A, Eckstein G, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/45\">",
"      Tieder M, Modai D, Samuel R, et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985; 312:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/46\">",
"      Tieder M, Arie R, Bab I, et al. A new kindred with hereditary hypophosphatemic rickets with hypercalciuria: implications for correct diagnosis and treatment. Nephron 1992; 62:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/47\">",
"      Lau YK, Wasserstein A, Westby GR, et al. Proximal tubular defects in idiopathic hypercalciuria: resistance to phosphate administration. Miner Electrolyte Metab 1982; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/48\">",
"      Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int 1998; 53:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/49\">",
"      Lloyd SE, Pearce SH, Fisher SE, et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379:445.",
"     </a>",
"    </li>",
"    <li>",
"     Scheinman SJ. Chapter 12: Dent's disease. In: Genetic Diseases of the Kidney, Lifton RP, Somlo S, Giebisch GH, Seldin DW (Eds), Academic Press, New York 2009.",
"    </li>",
"    <li>",
"     Drezner MK. Tumor-induced osteomalacia. In: Primer On the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th ed, Favus MJ (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/52\">",
"      Agus ZS. Oncogenic hypophosphatemic osteomalacia. Kidney Int 1983; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/53\">",
"      Salassa RM, Jowsey J, Arnaud CD. Hypophosphatemic osteomalacia associated with \"nonendocrine\" tumors. N Engl J Med 1970; 283:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/54\">",
"      Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 1984; 77:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/55\">",
"      Reyes-M&uacute;gica M, Arnsmeier SL, Backeljauw PF, et al. Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol 2000; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/56\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2001. A 14-year-old with abnormal bones and a sacral mass. N Engl J Med 2001; 345:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/57\">",
"      Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 1997; 12:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/58\">",
"      Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994; 330:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/59\">",
"      Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995; 80:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/60\">",
"      Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/61\">",
"      Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 1999; 25:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/62\">",
"      Seufert J, Ebert K, M&uuml;ller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001; 345:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/63\">",
"      Rhee Y, Lee JD, Shin KH, et al. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf) 2001; 54:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/64\">",
"      Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002; 359:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/65\">",
"      Chong WH, Yavuz S, Patel SM, et al. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab 2011; 96:3599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/66\">",
"      Ito N, Shimizu Y, Suzuki H, et al. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med 2010; 268:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21209/abstract/67\">",
"      Paglia F, Dionisi S, Minisola S. Octreotide for tumor-induced osteomalacia. N Engl J Med 2002; 346:1748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5802 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21209=[""].join("\n");
var outline_f20_45_21209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31918878\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      X-LINKED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30486902\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30486909\">",
"      Hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AUTOSOMAL DOMINANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      AUTOSOMAL RECESSIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HYPOPHOSPHATEMIA WITH HYPERCALCIURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypophosphatemic rickets with hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dent's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Idiopathic hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TUMOR-INDUCED OSTEOMALACIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31918878\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25831617\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5802|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/17/38174\" title=\"figure 1\">",
"      Mechanisms hereditary hypophosphatemic rickets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_45_21210="Treatment of hypertension in patients with diabetes mellitus";
var content_f20_45_21210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypertension in patients with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21210/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21210/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21210/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21210/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/45/21210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/45/21210/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/45/21210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration of diabetes is different [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Among those with type 1 diabetes, the incidence of hypertension rises from 5 percent at 10 years, to 33 percent at 20 years, and 70 percent at 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/2\">",
"     2",
"    </a>",
"    ]. There is a",
"    <strong>",
"     close relation",
"    </strong>",
"    between the prevalence of hypertension and increasing albuminuria. The blood pressure typically begins to rise within the normal range at or within a few years after the onset of moderately increased albuminuria (the new term for what was previously called \"microalbuminuria\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/4\">",
"     4",
"    </a>",
"    ]) and increases progressively as the renal disease progresses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link&amp;anchor=H10#H10\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These features were illustrated in a study of 981 patients who had type 1 diabetes for five or more years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/3\">",
"     3",
"    </a>",
"    ]. Hypertension was present in 19 percent of patients with normoalbuminuria, 30 percent with high albuminuria, and 65 percent with severely increased albuminuria (the new term for what was previously called \"macroalbuminuria\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/4\">",
"     4",
"    </a>",
"    ]). The incidence of hypertension eventually reaches 75 to 85 percent in patients with progressive diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk of hypertension is highest in blacks, who are also at much greater risk for renal failure due to diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The findings are different in patients with type 2 diabetes. In a series of over 3500 newly diagnosed patients, 39 percent were already hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/6\">",
"     6",
"    </a>",
"    ]. In approximately one-half of these patients, the elevation in blood pressure (BP) occurred",
"    <strong>",
"     before",
"    </strong>",
"    the onset of moderately increased albuminuria. Hypertension was strongly associated with obesity and, not surprisingly, the hypertensive patients were at increased risk for cardiovascular morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis of hypertension in patients with diabetes mellitus and the three major treatment issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The evidence supporting benefit from the treatment of hypertension",
"     </li>",
"     <li>",
"      The choice of antihypertensive drugs",
"     </li>",
"     <li>",
"      The goal blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the development of diabetic nephropathy, at least three other factors have been proposed to contribute to hypertension in diabetes: hyperinsulinemia, extracellular fluid volume expansion, and increased arterial stiffness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hyperinsulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinsulinemia, due to insulin resistance in type 2 diabetes or to insulin administration, may increase systemic blood pressure. In one report of 80 type 2 diabetic patients begun on insulin, the blood pressure rose from",
"    <span class=\"nowrap\">",
"     132/81",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     148/89",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/7\">",
"     7",
"    </a>",
"    ]. This hypertensive response, although not noted in all studies, may be mediated by concurrent weight gain and by the prohypertensive effect of insulin. Hyperinsulinemia may be a link to explain the association between obesity and hypertension both in nondiabetic patients and those with type 2 diabetes, since insulin can increase sympathetic activity and promote renal sodium retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Volume expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium retention and volume expansion may be induced both by insulin and the hyperglycemia-induced increase in the filtered glucose load [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. The excess filtered glucose is reabsorbed (as long as there is only moderate hyperglycemia) in the proximal tubule via a sodium-glucose cotransporter, resulting in a parallel rise in sodium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, salt loading tends to raise the blood pressure, an effect that can be reversed by salt restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Increased arterial stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes have increased vascular stiffness, which is thought to be a consequence of increased protein glycation and, at a later stage, atheromatous disease. The reduction in arterial distensibility, which is seen with both impaired glucose tolerance and overt diabetes, can contribute to the rise in systolic pressure and is associated with mortality risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BENEFIT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early treatment of hypertension is particularly important in diabetic patients both to prevent cardiovascular disease and to minimize progression of renal disease and diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/10\">",
"     10",
"    </a>",
"    ]. Among patients with type 2 diabetes, the benefits of tight blood pressure control may be as great or greater than the benefit of strict glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapy should include nonpharmacologic methods, such as weight reduction, increased consumption of fresh fruits, vegetables, and low-fat dairy products, exercise, salt restriction, and avoidance of smoking and excess alcohol ingestion. This is consistent with the American Heart Association and the American Diabetes Association 2007 guidelines, which state that, among patients with a systolic blood pressure of 130 to 139 mmHg, or a diastolic pressure of 80 to 89 mmHg, initial therapy should consist of nonpharmacologic methods [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/12\">",
"     12",
"    </a>",
"    ]. If target blood pressure is not achieved after three months, treatment with pharmacological agents should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since hypertension places diabetic patients at high risk for cardiovascular complications, all diabetic patients with persistent blood pressures above",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg should be started on antihypertensive drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Successful implementation of nonpharmacologic therapy may permit later reduction in the dose or number of antihypertensive agents.",
"   </p>",
"   <p>",
"    Intensive drug therapy is unequivocally protective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/11,13,15-19\">",
"     11,13,15-19",
"    </a>",
"    ]. In addition, prior observations concerning adverse effects of various antihypertensive drugs are now understood to be due in part to the administration of inappropriately high doses of diuretics and noncardioselective beta-blockers.",
"   </p>",
"   <p>",
"    Evidence of benefit from treating hypertension in type 2 diabetes has come from multiple trials, including UKPDS, ADVANCE, and HOT. The separate issue of goal blood pressure is discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     UKPDS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the UKPDS, 1148 patients with type 2 diabetes (mean baseline blood pressure",
"    <span class=\"nowrap\">",
"     160/94",
"    </span>",
"    mmHg) were randomly assigned to a goal blood pressure less than",
"    <span class=\"nowrap\">",
"     150/85",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     &lt;180/105",
"    </span>",
"    mmHg using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    as primary therapy; the achieved blood pressures in the two groups were",
"    <span class=\"nowrap\">",
"     144/82",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     154/87",
"    </span>",
"    mmHg, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At eight to nine years, patients with the lower blood pressures had a 24 percent reduction in diabetes-related end points, including microvascular disease (37 versus 49 percent, (",
"    <a class=\"graphic graphic_figure graphicRef77963 \" href=\"UTD.htm?26/52/27469\">",
"     figure 1",
"    </a>",
"    )), a 32 percent reduction in deaths related to diabetes (24 versus 35 percent), 44 percent fewer strokes, and a 34 and 47 percent reduction in significant deterioration in retinopathy and visual acuity, respectively.",
"   </p>",
"   <p>",
"    These benefits required continued maintenance of a lower blood pressure. In the UKPDS, there was a median of eight years of post-trial monitoring in which no attempt was made to maintain the assigned therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/20\">",
"     20",
"    </a>",
"    ]. The greater reduction in blood pressure and the lower risk of complications in the patients assigned to tight blood pressure control was lost within two years of termination and the significant improvements in clinical end points were not sustained.",
"   </p>",
"   <p>",
"    A subsequent observational report that utilized data from the UKPDS trial evaluated the risk of complications according to the systolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/21\">",
"     21",
"    </a>",
"    ]. There was an inverse correlation between the updated mean systolic blood pressure and the aggregate end point at 10 year follow-up for any complication related to diabetes (myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or death from peripheral artery disease, death from hyperglycemia or hypoglycemia, heart failure, vitreous hemorrhage, retinal photocoagulation, and cataract extraction). Each 10 mmHg reduction in systolic pressure was associated with a 12 percent risk reduction; the lowest risk occurred at a systolic pressure below 120 mmHg (",
"    <a class=\"graphic graphic_figure graphicRef77963 \" href=\"UTD.htm?26/52/27469\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, UKPDS was not designed to assess the efficacy of systolic pressures below 140 mmHg. Thus, these observations provide",
"    <strong>",
"     no evidence",
"    </strong>",
"    of a cause-and-effect relationship between lower systolic pressures and better patient outcomes. The ACCORD BP trial described below specifically addressed the issue of goal blood pressure less than 120 mmHg and found no benefit. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'ACCORD BP trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HOT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The details of the HOT trial are described separately. Summarized briefly, almost 19,000 patients (average pretreatment blood pressure of",
"    <span class=\"nowrap\">",
"     170/105",
"    </span>",
"    mmHg) were randomly assigned to target diastolic pressures of &le;90, &le;85, or &le;80 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/17\">",
"     17",
"    </a>",
"    ]. However, less separation in the diastolic blood pressure was achieved among the three target groups than had been planned as the mean diastolic blood pressures attained in the three groups were",
"    <span class=\"nowrap\">",
"     144/85,",
"    </span>",
"    <span class=\"nowrap\">",
"     141/83,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     140/81",
"    </span>",
"    mmHg, respectively. Among the 3000 patients with diabetes, but not in other patients, the relative risk of a cardiovascular event was significantly reduced in the &le;80 mmHg group compared to the &le;90 mmHg group (RR 0.49, 95% CI 0.29-0.81). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H11#H11\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'HOT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ADVANCE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ADVANCE trial was designed to evaluate the effect of intensive blood pressure and glycemic control on cardiovascular disease in patients with long-standing type 2 diabetes at high risk for vascular disease. The results of the glycemic control arm are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H14#H14\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'ADVANCE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ADVANCE trial is the only major",
"    <strong>",
"     placebo-controlled",
"    </strong>",
"    randomized trial that specifically evaluated antihypertensive therapy in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the attained blood pressures in ADVANCE were lower than in the UKPDS and HOT trials described above.",
"   </p>",
"   <p>",
"    ADVANCE compared the use of a fixed combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/24/34183?source=see_link\">",
"     perindopril-indapamide",
"    </a>",
"    to placebo in over 11,000 patients with type 2 diabetes. The majority of patients had a history of hypertension and the mean blood pressure at baseline was",
"    <span class=\"nowrap\">",
"     145/81",
"    </span>",
"    mmHg. A target blood pressure was not used to guide protocol therapy, and all other agents, except ACE inhibitors and thiazides, were initiated at the discretion of the treating physicians. The primary end points were macrovascular events (death from cardiovascular disease, nonfatal stroke or nonfatal myocardial infarction) or microvascular events (development of proteinuria, doubling of serum creatinine, initiation of renal replacement therapy, death due to renal causes, or retinopathy).",
"   </p>",
"   <p>",
"    After a mean of 4.3 years, the following significant differences were observed in the group assigned to active treatment compared with placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in mean blood pressure by",
"      <span class=\"nowrap\">",
"       5.6/2.2",
"      </span>",
"      mmHg. The mean attained blood pressures were approximately",
"      <span class=\"nowrap\">",
"       134.5/74",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       140/76",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      A lower rate of major macrovascular or microvascular events (15.5 versus 16.8 percent).",
"     </li>",
"     <li>",
"      A lower rate of cardiovascular mortality (3.8 versus 4.6 percent) and all-cause mortality (7.3 versus 8.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, lower blood pressures were associated with improved cardiovascular outcomes. Other benefits, which are discussed separately, included lower rates of development and progression of diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of diabetic nephropathy\", section on 'Renal protection with ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GOAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major guidelines have suggested that the goal blood pressure in patients with diabetes mellitus is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/13,14,22\">",
"     13,14,22",
"    </a>",
"    ]. Two small trials (Normotensive ABCD and SANDS) and the large ACCORD BP trial addressed the value of lower goal blood pressures in patients with diabetes, with mean attained systolic pressures below 120 mmHg in the aggressive therapy groups in SANDS and ACCORD BP. A meta-analysis of the ACCORD BP, ABCD, and HOT trial (discussed above) suggested that intensive blood pressure lowering in patients with diabetes significantly lowers the incidence of stroke (2.0 versus 3.1 percent) but does",
"    <strong>",
"     not",
"    </strong>",
"    significantly lower the risk of mortality (5.5 versus 6.3 percent) or myocardial infarction (7.9 versus 8.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normotensive ABCD trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normotensive Appropriate Blood pressure Control in Diabetes (ABCD) trial, 480 patients with type 2 diabetes were randomly assigned to placebo (moderate control) or to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    and a target diastolic blood pressure of 10 mmHg below the baseline level (intensive control) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/24\">",
"     24",
"    </a>",
"    ]. The mean attained blood pressures for the moderate and intensive control groups were",
"    <span class=\"nowrap\">",
"     137/81",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     128/75",
"    </span>",
"    mmHg, respectively.",
"   </p>",
"   <p>",
"    At follow-up at five years, there was no difference between the two groups in creatinine clearance, which was the primary end point. Intensive blood pressure control was associated with significant reductions in some secondary end points, such as progression of retinopathy (34 versus 46 percent), of normoalbuminuria to moderately increased albuminuria (formerly, \"microalbuminuria\"), and of moderately increased albuminuria to severely increased albuminuria (formerly \"macroalbuminuria\").",
"   </p>",
"   <p>",
"    There was no reduction in the rate of all cardiovascular events with intensive antihypertensive therapy (myocardial infarction, stroke, heart failure, and cardiovascular death; 20.2 versus 19.8 percent), although there was a significant reduction in stroke. A greater blood pressure dependence with stroke risk compared with coronary risk has been noted in the ACCORD BP trial discussed in the following section and in other trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H271902655#H271902655\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Stroke as an outcome of interest'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ACCORD BP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Action to Control Cardiovascular Risk in Diabetes blood pressure trial (ACCORD BP) randomly assigned 4733 patients with type 2 diabetes who had cardiovascular disease or at least two additional risk factors for cardiovascular disease to either intensive therapy (goal systolic blood pressure less than 120 mmHg) or standard therapy (goal systolic blood pressure less than 140 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/25\">",
"     25",
"    </a>",
"    ]. These goals were reached as the mean attained blood pressures in the two groups were 119.3 and 133.5 mmHg, respectively, compared to",
"    <span class=\"nowrap\">",
"     139/76",
"    </span>",
"    mmHg at baseline.",
"   </p>",
"   <p>",
"    At a mean follow-up of 4.7 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the annual rate of the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes between the intensive versus standard therapy groups (1.87 versus 2.09 percent, hazard ratio 0.88, 95% CI 0.73-1.06).",
"     </li>",
"     <li>",
"      There was no difference in the annual all-cause mortality rate between intensive and standard therapy groups (1.28 versus 1.19 percent) or in the rate of death from cardiovascular causes between groups (0.52 versus 0.49 percent).",
"     </li>",
"     <li>",
"      Intensive therapy was associated with significant reductions in the annual rates of total stroke and nonfatal stroke (0.32 versus 0.53 percent, hazard ratio 0.59, 95% CI 0.39-0.89, for total stroke and 0.30 versus 0.47 percent, HR 0.63, 95% CI 0.41-0.96, for nonfatal stroke).",
"     </li>",
"     <li>",
"      Serious adverse events attributable to antihypertensive drugs (eg, hypotension, syncope, bradycardia or arrhythmia, hyperkalemia, angioedema, and renal failure) occurred significantly more frequently in the intensive versus standard therapy group (3.3 versus 1.3 percent). Intensive therapy was also associated with a significantly higher rate of an increase in serum creatinine of more than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      in men or more than 1.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (115",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in women).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H227425787\">",
"    <span class=\"h2\">",
"     SANDS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the SANDS trial, 499 American Indian men and women with type 2 diabetes who were &ge;40 years of age and had no history of prior cardiovascular disease events were randomly assigned to standard target values for systolic blood pressure and LDL-cholesterol and systolic pressure (&le;130 mmHg and &le;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively), or to more aggressive targets (&le;115 mmHg and &le;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At three years, the mean attained systolic blood pressures were 117 and 129 in the aggressive and standard therapy groups, respectively. Aggressive therapy was associated with less progression of atherosclerosis and a greater reduction in left ventricular mass index on echocardiography. However, there was no difference in clinical cardiovascular events between the two groups (1.6 versus 1.5 per 100 person-years) and aggressive therapy was associated with significantly more adverse events related to antihypertensive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Trials of angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have been performed that compared angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) with placebo in patients at increased cardiovascular risk who had a baseline systolic blood pressure below 140 but mostly above 130 mmHg. Some but not all trials demonstrated improved outcomes in patients treated with active therapy but any benefit seems more likely to be due to lowering of the blood pressure rather than a specific effect of angiotensin inhibition. The outcomes were similar in patients with or without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. These trials are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H6#H6\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary and conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hypertension in diabetic patients was associated with significant clinical benefits in three major randomized trials: UKPDS (mean attained blood pressure",
"    <span class=\"nowrap\">",
"     144/82",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     154/87",
"    </span>",
"    mmHg with less aggressive therapy), in HOT",
"    <span class=\"nowrap\">",
"     (140/81",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     144/85",
"    </span>",
"    mmHg with less aggressive therapy), and in ADVANCE (mean attained blood pressure",
"    <span class=\"nowrap\">",
"     134.5/74",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     140/76",
"    </span>",
"    mmHg with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/11,17,18\">",
"     11,17,18",
"    </a>",
"    ]. These observations support a goal blood pressure for diabetic patients of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg, as recommended in most other patients with hypertension. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Benefit of treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major guidelines published before ACCORD BP suggested that the goal blood pressure in patients with diabetes mellitus should be less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/13,14,22\">",
"     13,14,22",
"    </a>",
"    ]. Supportive evidence comes from ABCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/24\">",
"     24",
"    </a>",
"    ], the stroke benefit in ACCORD BP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/25\">",
"     25",
"    </a>",
"    ], and in patients with diabetic nephropathy and proteinuria in whom weak evidence suggests that such a goal may slow the rate of progression of the nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H34#H34\">",
"     \"Treatment of diabetic nephropathy\", section on 'Therapeutic goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACCORD BP trial of patients with type 2 diabetes at increased cardiovascular risk found no significant cardiovascular benefit and more drug side effects at a mean attained systolic pressure of 119.3 compared to 133.5 mmHg, with the exception of a reduction in stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/25\">",
"     25",
"    </a>",
"    ]. A number of other studies have found that the incidence of stroke but not coronary disease continues to fall at systolic pressures below 125 to 130 mmHg. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'ACCORD BP trial'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H271902655#H271902655\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Stroke as an outcome of interest'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We propose the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all patients with diabetes mellitus have a goal blood pressure less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      We suggest (a weaker recommendation) an attempt to lower the systolic pressure below 130 to 135 mmHg (preferably less than 130 mmHg) if it can be achieved without producing significant side effects.",
"     </li>",
"     <li>",
"      We recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg in patients with diabetic nephropathy and proteinuria (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more). Patients with moderately increased albuminuria (formerly \"microalbuminuria\") are treated similarly to diabetic patients without proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"       \"Treatment of diabetic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who fulfill the entry criteria in ACCORD BP (type 2 diabetes plus either cardiovascular disease or at least two additional risk factors for cardiovascular disease), the authors and reviewers of this topic suggest that the risks and burdens of aiming for a goal systolic pressure of less than 120 mmHg (more side effects, extra patient visits, and increased cost) plus the lack of experience of almost all physicians in attaining such a goal may be too great a burden to achieve the small reduction in stroke that may be attained (absolute benefit 1 in 89 patients at five years). However, such a goal may be considered in highly motivated patients who would accept more aggressive antihypertensive therapy to further reduce their risk of stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHOICE OF ANTIHYPERTENSIVE DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ALLHAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ALLHAT trial is by far the largest prospective study of the treatment of mild hypertension and assessed the efficacy of different medications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/33\">",
"     33",
"    </a>",
"    ]. Over 33,000 patients (36 percent had type 2 diabetes) with hypertension (mean",
"    <span class=\"nowrap\">",
"     146/84",
"    </span>",
"    mmHg) and at least one other coronary risk factor were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    ; a fourth arm of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    therapy was prematurely terminated because of an increased incidence of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcomes in the diabetic patients were not different from those in the trial as a whole. Each of three drug classes was associated with equivalent rates of the primary outcome of coronary heart disease death and nonfatal myocardial infarction. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    was",
"    <strong>",
"     superior",
"    </strong>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    in preventing new onset heart failure (relative risk 1.42 and 1.22, respectively, compared with chlorthalidone). This benefit may have been due at least in part to a greater degree of blood pressure reduction with chlorthalidone.",
"   </p>",
"   <p>",
"    In terms of adverse effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    was associated with a mild rise in the plasma glucose. Among nondiabetic patients, for example, an elevation in fasting glucose to values &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which is a diagnostic criterion for type 2 diabetes, occurred significantly more often with chlorthalidone (11.6 versus 9.8 and 8.1 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary salt restriction and low-dose thiazide diuretics (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , which acts at the same site in the kidney as the thiazides) are effective in hypertensive diabetic patients, acting at least in part by reversing the underlying tendency to volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, mild fluid loss increases the antihypertensive effect of an angiotensin inhibitor, since the hypovolemia-induced rise in renin and angiotensin II production that normally limits the diuretic response is diminished. ACE inhibitors also may minimize or prevent some of the metabolic complications associated with diuretic therapy, such as hypokalemia (by lowering angiotensin II-induced aldosterone release), hyperlipidemia (via an unknown mechanism), and hyperuricemia (perhaps by decreasing proximal sodium and urate reabsorption) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolic complications and a possible increase in cardiovascular risk have been a major concern with high doses of diuretics in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/36\">",
"     36",
"    </a>",
"    ]. However, as shown in ALLHAT and other studies, the increase in blood glucose is usually quite small with low-dose therapy, such as 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. In addition, low-dose thiazide therapy minimizes the fall in plasma potassium concentration and the rise in triglyceride and uric acid concentrations in diabetic patients compared to higher thiazide doses (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H37#H37\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Thiazide diuretics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Angiotensin inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When antihypertensive drugs are used, angiotensin converting enzyme (ACE) inhibitors offer a number of advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They lower the blood pressure, although no drug is likely to be sufficient as monotherapy.",
"     </li>",
"     <li>",
"      They have no specific toxicity, except for cough and raising the plasma potassium concentration in patients with underlying hyperkalemia or renal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They have no adverse effects on lipid metabolism.",
"     </li>",
"     <li>",
"      They may lower the plasma glucose concentration by increasing responsiveness to insulin. In one study, for example, 130 patients with type 2 diabetes were stabilized for three months; the subsequent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      for four months led to a reduction in hemoglobin A1C values from 8.6 to 6.5 percent with no change in insulin dose, dietary intake, or body weight [",
"      <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/39\">",
"       39",
"      </a>",
"      ]. A possible effect of ACE inhibitors in reducing the incidence of new onset type 2 diabetes is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H30#H30\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Inhibition of angiotensin II'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They protect against the progression of moderately increased albuminuria (formerly \"microalbuminuria\") and severely increased albuminuria (formerly \"macroalbuminuria\") due to type 1 and 2 diabetes and have been evaluated for primary prevention of diabetic nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"       \"Microalbuminuria in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"       \"Treatment of diabetic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They may slow the progression of retinopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H6#H6\">",
"       \"Prevention and treatment of diabetic retinopathy\", section on 'Is angiotensin inhibition preferred?'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in high risk patients have led some experts to conclude that these agents have a unique cardiovascular benefit in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/28,40\">",
"     28,40",
"    </a>",
"    ]. However, the available data are more consistent with the conclusion that the achieved blood pressure, rather than the specific drug or drug class used, is the principal determinant of this specific benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare complication of ACE inhibition, particularly in patients with near-normal glycemic control, is hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II receptor blockers (ARBs) appear to have the same benefits as ACE inhibitors described in the preceding section. Two major trials, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    Diabetic Nephropathy Trial (IDNT) and the RENAAL trial, demonstrated a clear benefit in terms of renoprotection with ARBs in patients with nephropathy due to type 2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This was also seen in early type 2 diabetes with normal kidney function and normoalbuminuria or moderately increased albuminuria (formerly \"microalbuminuria\") in the (DETAIL) trial, in which an ACE inhibitor was at least as effective as an ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although both of the IDNT and RENAAL trials found that patients who received an ARB had significant reductions in the development of and subsequent hospitalization for heart failure, neither trial showed a significant cardiovascular mortality reduction with these agents. A possible explanation is that the two ARB trials were underpowered and of too short duration to detect a possible cardiovascular benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the LIFE trial, in which the efficacy of an ARB was compared with a beta blocker, reported a significant reduction in cardiovascular morbidity and mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    in a subset of high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the RENAAL and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    studies, the LIFE trial (which enrolled a total 9193 patients, of whom 1105 were diabetic) was sufficiently powered to provide comparative efficacy data. The entry criteria included clinical hypertension (sitting blood pressure 160 to",
"    <span class=\"nowrap\">",
"     200/95",
"    </span>",
"    to 115 mmHg) and electrocardiographic evidence of left ventricular hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the LIFE diabetic trial substudy, all diabetic patients (most of whom had type 2 diabetes) between the ages of 55 and 80 who fulfilled the entry criteria were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    -based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/47\">",
"     47",
"    </a>",
"    ]. The substudy was performed in parallel with and analyzed similarly as the larger LIFE study. The primary end point was one of the following events: cardiovascular death, myocardial infarction, or stroke, while the composite end point was any one of these primary events.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    resulted in marked benefits. At a mean follow-up of 4.7 years, the ARB was associated with significant reductions in the primary composite end point (18 versus 23 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ), cardiovascular mortality (6 versus 10 percent), and total mortality (11 versus 17 percent).",
"   </p>",
"   <p>",
"    The greater benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    may have been a consequence of the greater regression in left ventricular hypertrophy (LVH) independent of blood pressure response. In two subsequent reports from the LIFE trial, regression of LVH by both electrocardiographic and echocardiographic criteria was significantly correlated with a reduction in the incidence of the primary end point [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subgroup analysis of the ONTARGET trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    in 6391 patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/50\">",
"     50",
"    </a>",
"    ]. The primary outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. There was no difference in the composite primary outcome between these groups.",
"   </p>",
"   <p>",
"    A possible effect of ARBs in reducing the incidence of new onset type 2 diabetes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H30#H30\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Inhibition of angiotensin II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     ACE inhibitor plus ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is whether an ARB should be given with an ACE inhibitor. In the CALM trial of 199 hypertensive patients with type 2 diabetes with moderately increased albuminuria (formerly \"microalbuminuria\"),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (16",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    produced equivalent reductions in blood pressure that were significantly less than the response seen with combination therapy",
"    <span class=\"nowrap\">",
"     (14.1/10.7",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     16.7/10.4",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     25.3/16.3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/51\">",
"     51",
"    </a>",
"    ]. Candesartan also lowered albuminuria but to a lesser degree than lisinopril or combination therapy. However, combination therapy was not compared to higher doses of either agent alone.",
"   </p>",
"   <p>",
"    In the subgroup analysis of the ONTARGET trial cited above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    , and combination therapy were compared in 6365 patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/50\">",
"     50",
"    </a>",
"    ]. There was no difference in the composite primary outcome of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure between these groups. However, in the entire cohort, which comprised 25,620 patients with vascular disease or diabetes, there was an increase in adverse side effects (including a possible increase in mortality) in patients who received both agents, compared to those who received ramipril alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the findings on ONTARGET, we do NOT recommend combination therapy with an ACE inhibitor and ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somewhat similar considerations (efficacy and lack of adverse effects of lipid or carbohydrate metabolism) apply to the nondihydropyridine calcium channel blockers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/54\">",
"     54",
"    </a>",
"    ]. However, an ACE inhibitor is still preferred as initial therapy, in part because it appears to be superior to verapamil for the primary prevention of diabetic nephropathy among hypertensive patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two relatively small initial trials suggested increased cardiovascular complications with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    compared to an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, two major hypertension trials, HOT and Syst-Eur, found no evidence of a deleterious effect from a long-acting dihydropyridine in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/17,54,58\">",
"     17,54,58",
"    </a>",
"    ]. In addition, amlodipine was associated with similar rates of coronary mortality and nonfatal myocardial infarction as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    in the much larger ALLHAT trial of patients with hypertension and risk factors for cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/33\">",
"     33",
"    </a>",
"    ]. However, a",
"    <strong>",
"     higher",
"    </strong>",
"    rate of heart failure among diabetic patients was observed with amlodipine compared with chlorthalidone (relative risk 1.42, 95% CI 1.23-1.64), a finding also observed among patients without diabetes.",
"   </p>",
"   <p>",
"    Similar results in terms of safety and efficacy were reported in a 2004 meta-analysis of 14 studies that evaluated calcium channel blockers in hypertensive diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate question is the role of calcium channel blockers in combination therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     Amlodipine",
"    </a>",
"    may provide better protection against cardiovascular events than low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    when both are used in combination with an ACE inhibitor. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Combination therapy and ACCOMPLISH'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are concerns about masking of hypoglycemic symptoms and possible exacerbation of peripheral artery disease, beta blockers are effective therapy for hypertension in diabetic patients. In the UKPDS study of patients with type 2 diabetes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    in terms of both blood pressure lowering and protection against microvascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/60\">",
"     60",
"    </a>",
"    ]. In the LIFE diabetic parallel study, however,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    provided significantly more protection from adverse cardiovascular outcomes than atenolol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    is a combined nonselective beta- and alpha-1 adrenergic antagonist that improves survival in patients with heart failure and may have certain advantages compared to other beta blockers in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was best addressed in the GEMINI trial of 1235 patients with hypertension",
"    <span class=\"nowrap\">",
"     (&gt;130/80",
"    </span>",
"    mmHg) and type 2 diabetes; all patients were treated with an ACE inhibitor or ARB, while other antihypertensive drugs were discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/61\">",
"     61",
"    </a>",
"    ]. The patients were then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    (6.25 to 25 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (50 to 200 mg twice daily);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    and a dihydropyridine calcium channel blocker were added as necessary to achieve a BP below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    was associated with the following significant benefits at five months; the blood pressure was similar in the two groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No change in A1C compared to a mean 0.15 percent increase with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      and an increase in insulin sensitivity (9.1 percent) compared to no change with metoprolol. In addition, fewer patients withdrew from the trial because of worsening glycemic control (0.6 versus 2.2 percent).",
"     </li>",
"     <li>",
"      A lower rate of progression to moderately increased albuminuria (formerly \"microalbuminuria\") in patients in whom this was not present at baseline (6.6 versus 11.1 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ) and a 16 percent relative reduction in albumin excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of this short-term trial is that cardiovascular outcomes could not be assessed.",
"   </p>",
"   <p>",
"    The modest worsening of glycemic control seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    has also been noted in studies of other beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], and beta blockers have been associated in nondiabetic patients with an increased incidence of new onset diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/63\">",
"     63",
"    </a>",
"    ]. The Atherosclerosis Risk In Communities study (ARIC) study found that, among hypertensive patients who did not have diabetes, beta blocker therapy (but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ) was associated with a 28 percent increased risk of developing type 2 diabetes compared to no antihypertensive therapy; this relationship was not seen with thiazides, calcium channel blockers, or ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/64\">",
"     64",
"    </a>",
"    ]. GEMINI showed that the increased risk of this adverse effect of metoprolol also occurs in diabetic patients treated with ACE inhibitors or ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Alpha blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not widely used as primary therapy in diabetes because of side effects such as orthostatic hypotension, peripheral alpha blockers (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ) are as effective in lowering blood pressure as ACE inhibitors and calcium channel blockers and have a more favorable metabolic profile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/66\">",
"     66",
"    </a>",
"    ]. However, in the ALLHAT trial, the doxazosin arm was prematurely discontinued due to an increased rate of new onset heart failure compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'ALLHAT trial'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these data, alpha blockers should",
"    <strong>",
"     not",
"    </strong>",
"    be used as primary therapy for hypertension. However, they may prove useful as add-on therapy, particularly in older men with symptomatic prostatism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Combination therapy and ACCOMPLISH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative efficacy of combination therapy in hypertensive patients was evaluated in the ACCOMPLISH trial in which 11,506 patients with hypertension (60 percent with diabetes) were randomly assigned to combination therapy consisting of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    or benazepril plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/69\">",
"     69",
"    </a>",
"    ]. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death and coronary revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H17#H17\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ACCOMPLISH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the 6946 patients with diabetes, the primary end point was achieved significantly less often in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    group (8.8 versus 11 percent, hazard ratio 0.79, 95% CI 0.68-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/45/21210/abstract/70\">",
"     70",
"    </a>",
"    ]. The benefit was similar to that in patients without diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and time of development of hypertension in patients with diabetes mellitus varies with the type of diabetes. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction and prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with type 1 diabetes, the incidence of hypertension rises from 5 percent at 10 years' duration, to 33 percent at 20 years, and 70 percent at 40 years. The blood pressure typically begins to rise within the normal range at or within a few years after the onset of moderately increased albuminuria (formerly \"microalbuminuria\") and increases progressively as the renal disease progresses.",
"     </li>",
"     <li>",
"      Among patients with type 2 diabetes, as many as 40 percent are hypertensive at the time of diagnosis and, in approximately one-half of these patients, the elevation in blood pressure occurred",
"      <strong>",
"       before",
"      </strong>",
"      the onset of moderately increased albuminuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antihypertensive agents in diabetic patients is based upon their ability to prevent adverse cardiovascular events and to slow progression of renal disease, if present. The choice is not based upon retinopathy end points since comparative trials have not demonstrated superiority of one agent over another for retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ALLHAT trial, diabetic patients had a significantly lower rate of new onset heart failure with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      . This effect may have been due at least in part to a lower attained blood pressure with chlorthalidone. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'ALLHAT trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the ACCOMPLISH trial, the combination of an ACE inhibitor and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      provided better protection against cardiovascular outcomes in diabetic patients than the combination of an ACE inhibitor and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Combination therapy and ACCOMPLISH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitors and ARBs protect against the development of progressive nephropathy due to type 1 and 2 diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"       \"Treatment of diabetic nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"       \"Microalbuminuria in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ACE inhibitor or ARB is clearly preferred as initial therapy in any hypertensive diabetic patient who has moderately increased albuminuria (formerly \"microalbuminuria\") or severely increased albuminuria (formerly \"macroalbuminuria\") in an attempt to slow renal disease progression. Most experts will also begin with an ACE inhibitor or ARB in hypertensive diabetic patients without proteinuria. This is unlikely to occur in patients with type 1 diabetes in whom moderately increased albuminuria typically precedes hypertension.",
"   </p>",
"   <p>",
"    Although ALLHAT found some better outcomes with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , this effect could have been related to the lower attained blood pressures with chlorthalidone. Thiazide diuretics have the disadvantage of an adverse effect on glucose metabolism. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'ALLHAT trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Monotherapy can attain goal blood pressure in some patients with diabetes and hypertension. This is most likely to occur in those with blood pressures that are only modestly above goal. However, combination therapy is eventually required in most patients. We suggest adding a long-acting dihydropyridine to the ACE inhibitor or ARB given the results of ACCOMPLISH. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Combination therapy and ACCOMPLISH'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H24#H24\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other antihypertensive drugs can be added if the blood pressure goal is still not achieved. If a beta blocker is given,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    may be the drug of choice because of potential benefits on glycemic control and lower rate of development of moderately increased albuminuria compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    . A loop diuretic is likely to be necessary in patients with renal disease or heart failure.",
"   </p>",
"   <p>",
"    Antihypertensive drugs, usually in combination, attain a blood pressure below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in over 80 percent of patients with diabetes and hypertension. Data on success rates of the goal of less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg are not as available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major guidelines, published before the ACCORD BP trial, suggested that the goal blood pressure in patients with diabetes mellitus is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. However, there are no convincing data supporting this approach, with the possible exception of patients with diabetic nephropathy and proteinuria in whom weak evidence suggests that such a goal may slow the rate of progression of the nephropathy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Goal blood pressure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of diabetic nephropathy\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures in all patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest (a weaker recommendation) an attempt to lower the systolic pressure below 130 to 135 mmHg (preferably less than 130 mmHg) if it can be achieved without producing significant side effects (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg compared with higher pressures in patients with diabetic nephropathy and proteinuria (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who fulfill the entry criteria in ACCORD BP (type 2 diabetes plus either cardiovascular disease or at least two additional risk factors for cardiovascular disease), the authors and reviewers of this topic suggest that the risks and burdens of aiming for a goal systolic pressure of less than 120 mmHg (more side effects, extra patient visits, and increased cost) plus the lack of experience of almost all physicians in attaining such a goal may be too great a burden to achieve the small reduction in stroke that may be attained (absolute benefit 1 in 89 patients at five years). However, such a goal may be considered in highly motivated patients who would accept more aggressive antihypertensive therapy to further reduce their risk of stroke.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/1\">",
"      Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/2\">",
"      Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/3\">",
"      Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/4\">",
"      KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. file://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/5\">",
"      Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/6\">",
"      Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/7\">",
"      Randeree HA, Omar MA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992; 15:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/8\">",
"      Nosadini R, Sambataro M, Thomaseth K, et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int 1993; 44:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/9\">",
"      Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/10\">",
"      Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/11\">",
"      Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/12\">",
"      Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/13\">",
"      Executive summary: Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/14\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/15\">",
"      Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/16\">",
"      Snow V, Weiss KB, Mottur-Pilson C, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/17\">",
"      Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/18\">",
"      Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/19\">",
"      Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/20\">",
"      Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/21\">",
"      Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/22\">",
"      Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/23\">",
"      McBrien K, Rabi DM, Campbell N, et al. Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med 2012; 172:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/24\">",
"      Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/25\">",
"      ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/26\">",
"      Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/27\">",
"      Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/28\">",
"      Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/29\">",
"      Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/30\">",
"      Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/31\">",
"      Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/32\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/33\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/34\">",
"      National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/35\">",
"      Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5:III132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/36\">",
"      Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/37\">",
"      Passmore AP, Whitehead EM, Crawford V, et al. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991; 81:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/38\">",
"      Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/39\">",
"      Alkharouf J, Nalinikumari K, Corry D, Tuck M. Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens 1993; 6:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/40\">",
"      Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/41\">",
"      Herings RM, de Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/42\">",
"      Morris AD, Boyle DI, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997; 20:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/43\">",
"      Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/44\">",
"      Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/45\">",
"      Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/46\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/47\">",
"      Lindholm LH, Ibsen H, Dahl&ouml;f B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/48\">",
"      Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/49\">",
"      Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/50\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/51\">",
"      Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/52\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/53\">",
"      Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/54\">",
"      Birkenh&auml;ger WH, Staessen JA. Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1999; 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/55\">",
"      Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/56\">",
"      Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/57\">",
"      Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000; 343:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/58\">",
"      Tuomilehto J, Rastenyte D, Birkenh&auml;ger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/59\">",
"      Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004; 116:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/60\">",
"      Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/61\">",
"      Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/62\">",
"      Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/63\">",
"      Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/64\">",
"      Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/65\">",
"      Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/66\">",
"      Giordano M, Matsuda M, Sanders L, et al. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/67\">",
"      Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 2000; 355:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/68\">",
"      Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/69\">",
"      Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/45/21210/abstract/70\">",
"      Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3829 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21210=[""].join("\n");
var outline_f20_45_21210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hyperinsulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Volume expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Increased arterial stiffness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BENEFIT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      UKPDS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVANCE trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GOAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normotensive ABCD trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACCORD BP trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H227425787\">",
"      SANDS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Trials of angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary and conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHOICE OF ANTIHYPERTENSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ALLHAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Angiotensin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - ACE inhibitor plus ARB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Alpha blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Combination therapy and ACCOMPLISH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Choice of antihypertensive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3829|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27469\" title=\"figure 1\">",
"      Systolic BP in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 2\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_45_21211="Types of heparin thrombocytopenia";
var content_f20_45_21211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinguishing characteristics of the two types of heparin-induced thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Type 1",
"      </td>",
"      <td class=\"subtitle1\">",
"       Type 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frequency",
"      </td>",
"      <td>",
"       10 to 20 percent",
"      </td>",
"      <td>",
"       1 to 3 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Timing of onset",
"      </td>",
"      <td>",
"       1 to 4 days",
"      </td>",
"      <td>",
"       5 to 10 days after start of heparin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nadir platelet count",
"      </td>",
"      <td>",
"       100,000/microL",
"      </td>",
"      <td>",
"       usually &gt;20,000/microL; median nadir 60,000/microL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antibody mediated",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thromboembolic sequelae",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       30 to 80 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemorrhagic sequelae",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Management",
"      </td>",
"      <td>",
"       Observe",
"      </td>",
"      <td>",
"       Cessation of heparin, alternative nonheparin anticoagulation to prevent thrombosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31:1449.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21211=[""].join("\n");
var outline_f20_45_21211=null;
var title_f20_45_21212="Cytokeratin stain pattern CUP";
var content_f20_45_21212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of unknown primary cancers based upon immunostaining for cytokeratin (CK) 7 and 20",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CK7+ CK20+",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urothelial tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucinous ovarian cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatic or biliary cancer",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CK7+ CK20-",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Non-small cell lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small cell lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breast cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometrial cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonmucinous ovarian cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesothelioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cancer of cervix",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CK7- CK20+",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colorectal cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Merkel cell cancer",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CK7- CK20-",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatocellular cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal cell cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prostate cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cell lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Head and neck cancer",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Dabbs D. Diagnostic Immunohistochemistry, 2nd ed, Churchill Livingstone, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21212=[""].join("\n");
var outline_f20_45_21212=null;
var title_f20_45_21213="ACEI v ARBs in AE";
var content_f20_45_21213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Actions of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiotensin and kinin pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left side of figure: ACE normally converts angiotension I to angiotension II, and ACE inhibitors (ACEIs) inhibit this reaction.",
"    <br>",
"     Right side of figure: In the presence of ACEIs, bradykinin is not degraded and binds to bradykinin B2 receptors.",
"     <div class=\"footnotes\">",
"      ACE: angiotensin converting enzyme; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21213=[""].join("\n");
var outline_f20_45_21213=null;
var title_f20_45_21214="Right atrial thrombus venogram";
var content_f20_45_21214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right atrial thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This venogram obtained by administration of contrast into the inferior vena cava demonstrates a large filling defect (arrows), adhering to the tip of a central line catheter in the right atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21214=[""].join("\n");
var outline_f20_45_21214=null;
var title_f20_45_21215="Retinopathy in WM";
var content_f20_45_21215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinopathy in Waldenstr&ouml;m macroglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retinal photograph from a patient with Waldenstr&ouml;m macroglobulinemia shows multiple hemorrhages and dilated, segmented, and tortuous retinal veins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_45_21215=[""].join("\n");
var outline_f20_45_21215=null;
